. 2016 Feb 2;35:23. doi: 10.1186/s13046-016-0303-5

Table 3.

Clinical trials of CQ-analogs combined with TMZ in cancer therapy

Studys	Type	Year of registration	Sponsor	Drugs	Tumor type	Targeted enrolment	Status	Major findings
NCT00486603 [41]	Phase I	2007	Sidney Kimmel Comprehensive Cancer Center	200, 400, 800 mg/day HCQ + 150-200 mg/m2/day TMZ for 5 d [q4wk] + RT	Newly diagnosed GBM	16	Complished	HCQ 600 mg/day was found to be the MTD in this combination.
NCT00486603 [41]	Phase II	2007	Sidney Kimmel Comprehensive Cancer Center	600 mg/day HCQ + 150-200 mg/m2/day TMZ for 5 d [q4wk] + RT	Newly diagnosed GBM	76	Complished	Median survival of 15.6 mos with survival rates at 12, 18, and 24 mo of 70%, 36%, and 25%. PK analysis indicated dose-proportional exposure for hCQ. AV in PBMC: patients with Cmax above 1785 ng/mL had a increased median AV change of 1.01.
NCT02378532^a	Phase I	2015	Maastricht Radiation Oncology	200-600 mg/day HCQ + 150-200 mg/m2/day TMZ for 5 d [q4wk] + RT	Newly diagnosed GBM	9	Not yet open	N/A
NCT01430351^a	Phase I	2011	M.D. Anderson Cancer Center	250 mg/day MFQ for 3 d/week+ 150 mg/m2/day TMZ for 5 d [q4wk]	Post-RT Glioblastoma	144	Recruiting participants	N/A

^a Further information can be found at http://clinicaltrials.gov